Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126763891 | 12676389 | 1 | I | 20160813 | 0 | 20160822 | 20160822 | DIR | 68.00 | YR | M | N | 205.00000 | LBS | 20160821 | N | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126763891 | 12676389 | 1 | PS | TOVIAZ | FESOTERODINE FUMARATE | 1 | Oral | Y | D | F10242030 | 20170630 | 0 | 17 | DF | COATED TABLET | QD | |||
126763891 | 12676389 | 3 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | 0 | ||||||||||||
126763891 | 12676389 | 5 | C | LOSARTAN. | LOSARTAN | 1 | 0 | ||||||||||||
126763891 | 12676389 | 7 | C | ATORVASTATIN | ATORVASTATIN | 1 | 0 | ||||||||||||
126763891 | 12676389 | 9 | C | BABY ASPIRIN | ASPIRIN | 1 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126763891 | 12676389 | 1 | Hypertonic bladder |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126763891 | 12676389 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126763891 | 12676389 | Constipation | |
126763891 | 12676389 | Headache | |
126763891 | 12676389 | Lactose intolerance |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126763891 | 12676389 | 1 | 20160731 | 20160816 | 0 |